Filenews 5 April 2021
Vaccines are the only effective weapon against coronavirus, but much of the scientific community believes they should be re-evaluated in a year's time because of the mutations. More specifically, according to recent research, two-thirds of infectious diseases claim that, due to mutations, the vaccines we now have in our hands will be ineffective in a year.
The research was carried out by the People's Vaccine Alliance and collected the views of 77 scientists. About 66% of epidemiologists and biologists who took part in the study believe that within a year, the coronavirus will mutate to such an extent that the first vaccines currently available will be ineffective. Of these, almost a fifth (18.2%) of those surveyed said they would like to see a increase in the number of people in work. believes that this could be done in the coming months, while a third (32.5%) believe that this could be done in the coming months. within nine months. 18.2% believe vaccines will become inadequate within almost two years. The most optimistic, less than an eighth (7.8%), said mutations could not make vaccines inadequate against coronavirus.
"The longer the vaccine travels, the more likely it is that new mutations will occur all the time that could affect the effectiveness of vaccines," dr. Devi Sridhar, professor in the Department of Medicine at the University of Edinburgh in Scotland, one of the epidemiologists who took part in this research. "At the same time the poorest countries are left without vaccines but, as recent history has shown, the coronavirus knows no borders," he adds.
Manufacturers Pfizer-BioNTech, Moderna and AstraZeneca are already working on their enhanced formula, while new news from Pfizer says tests on 12,000 volunteers have shown that the vaccine is effective against the South African mutation and is safe and effective after six months.
The pharmaceutical company Moderna also launched clinical trials on enhanced doses of the vaccine to determine whether it offers more effective protection against the South African strain. The volunteers who participated in the initial clinical trials last year received one of the three doses and will then compare the results with each other.
Source: ygeiamou.gr
